Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Subscribe Now
/Free Sign Up
 0
👀 Ones to watch: Undervalued stocks to buy before they report Q3 earnings See Undervalued Stocks
Close

Breaking News

UBS lifts its 2025 S&P 500 price target by 8%

Abbott Laboratories (ABT)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Abbott Labs's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
117.25 +1.13    +0.97%
14/10 - Closed. Currency in USD
Pre Market
116.60
-0.65
-0.55%
9:07:00 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 3,674,100
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 115.98 - 117.58
Abbott Labs 117.25 +1.13 +0.97%

NYSE:ABT Financials

 
A brief overview of the NYSE:ABT financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Abbott over time.

Abbott Laboratories reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was USD 10,377 million compared to USD 9,978 million a year ago. Net income was USD 1,302 million compared to USD 1,375 million a year ago. Diluted earnings per share from continuing operations was USD 0.74 compared to USD 0.78 a year ago.For the six months, sales was USD 20,341 million compared to USD 19,725 million a year ago. Net income was USD 2,527 million compared to USD 2,693 million a year ago. Diluted earnings per share from continuing operations was USD 1.44 compared to USD 1.53 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ABT Income Statement

Gross margin TTM 55.47%
Operating margin TTM 17.98%
Net Profit margin TTM 13.65%
Return on Investment TTM 11.71%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Revenue 10377 9964 10241 10143
Gross Profit 5774 5512 5710 5538
Operating Income 1833 1535 2057 1769
Net Income 1302 1225 1594 1436

ABT Balance Sheet

Quick Ratio MRQ 1.02
Current Ratio MRQ 1.68
LT Debt to Equity MRQ 33.61%
Total Debt to Equity MRQ 37.76%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Assets 73017 72467 73214 72090
Total Liabilities 33457 33424 34387 34396
Total Equity 39560 39043 38827 37694

ABT Cash Flow Statement

Cash Flow/Share TTM 4.54
Revenue/Share TTM 23.41
Operating Cash Flow  14.24%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 1960 1025 3038 1877
Cash From Investing Activities -453 -425 -824 -634
Cash From Financing Activities -791 -1176 -2052 -2340
Net Change in Cash 703 -612 187 -1126
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

ABT Comments

Write your thoughts about Abbott Laboratories
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Aleksandr Rogovoy
Aleksandr Rogovoy Aug 23, 2024 11:50AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
sell 112.13
Reply
0 0
Report
Ciprian Gal
Ciprian Gal Jul 29, 2024 9:32AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
super expent
Reply
0 0
Report
Steve McIntosh
Steve McIntosh Jul 20, 2024 5:48PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
All I got from Abbott’s Freestyle was a severe staphylococcus infection and wound up in the emergency room at Santa Barbara Cottage Hospital. All Abbott did was ignore me and my condition. They win the booby prize for customer care.
Reply
0 0
Report
Steve McIntosh
Steve McIntosh Jul 20, 2024 2:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I am deeply troubled by the issues surrounding the Freestyle devices. After contracting a severe staphylococcus infection from the device, my concerns were exacerbated by Abbott's lack of prompt action for 8 months. Their customer support, located in the Philippines and Mexico City, presented challenges due to the absence of direct support in the US. This has led me to suspect a possible deliberate oversight on Abbott's part regarding staph infections caused by their devices. Moreover, online reports indicate that I am not alone in experiencing such infections. The culmination of these events resulted in a visit to the emergency room at a local hospital for urgent medical attention. Upon reaching out to CEO Robert Hunt with photographic evidence of the issue, I was disappointed to find that my concerns were not escalated to the head of customer service, Michael Taylor. Such negligence on the part of the CEO is unequivocally unacceptable and calls for immediate action. This situation demands swift and thorough investigation into the safety and efficacy of Abbott's Freestyle devices, as well as accountability for the handling of customer complaints at all levels of the organization.
Reply
0 0
Report
James Cooley
James Cooley Mar 15, 2024 3:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what baby formula is all these companies being sued for?
Reply
0 1
Report
Suraj Tschand
Suraj Tschand Mar 14, 2024 4:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ABT is a success story. There FreeStyle for diabetes is the best seller. The unit tells a diabetic person what foods cause the glucose spikes. The stock shot up because of their runaway successful Covid rapid tester. It has gone up by 20% this year and before we know it, it will be hitting $150.
Reply
1 2
Report
Mauro Mariotti
Mauro Mariotti Sep 27, 2023 9:52AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Caspita sotto 100....
Reply
0 0
Report
Michael Gad
Michael Gad Feb 10, 2023 9:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buy 108.3
Reply
0 2
Report
Jonah Garber
Jonah Garber Aug 08, 2022 1:45PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals
Reply
1 0
Report
wayne lim
wayne lim Aug 07, 2022 9:19AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
super boom
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Apple
Continue with Google
or
Sign up with Email